Healthcare / BiotechnologyNasdaqGS
$1.11
-0.04 (-3.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-32.2M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$22M
P/E
N/A
•EV/EBITDA
N/A
•ROE
235.1%
↑Gross Margin
N/A
•Debt/Equity
-0.52
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-84.0M · FCF $-41.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Net Income | $-84.0M | $-84.0M | $-56.8M | $-31.4M | $-51.7M | $-89.9M | $-76.8M | $-37.0M | $-12.5M |
| EBITDA | $-50.3M | $-50.3M | $-36.0M | $-26.8M | $-51.0M | $-90.0M | $-78.6M | $-39.0M | $-12.1M |
| EPS | -16.80 | -16.80 | -13.10 | -8.40 | -15.40 | -30.30 | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | -0.52 | -0.52 | 0.49 | 0.16 | 0.00 | — | — | — | — |
| Current Ratio | 2.92 | 2.92 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-41.8M | $-41.8M | $-32.2M | $-18.5M | $-44.2M | $-63.1M | $-50.9M | $-33.3M | $-11.9M |
| Returns | |||||||||
| ROE | 235.1% | 235.1% | -188.5% | -36.9% | -51.4% | -75.8% | -44.6% | -32.0% | 38.2% |
| Valuation | |||||||||
| P/B | — | — | 2.80 | 0.50 | 0.23 | — | — | — | — |
| Growth & Yield | |||||||||
| EPS Growth | -28.2% | -28.2% | -56.0% | 45.5% | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-89.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-13.10 → -16.80
Residual
-89.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.